Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

Complimentary Webinar Available

Posted 9/24/2023

Recent Hospital Controlled Substance Diversion Cases ? Cautionary Tales

Tuesday, October 3, 2023: 12:00-12:45

Hyman, Phelps & McNamara (HPM) invites you to join Director Larry Houck for a free webinar on the compliance lessons learned from recent hospital controlled substance diversion cases.

In this webinar you?ll learn:

  • How employees diverted controlled substances ? their methods are constantly evolving
  • What red flags were missed
  • DEA inspection priorities
  • Safeguards to minimize internal diversion
  • Best practices for maximizing diversion detection

Mr. Houck was a DEA Diversion Investigator for 15 years prior to joining HPM in 2001. He conducted numerous employee diversion investigations in the field and later served as Staff Coordinator in Diversion Control?s Liaison and Policy Section at DEA headquarters.

To register:

Back to all news

Sponsor Spotlight

COMPASS Pathways

COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more

All Sponsors